Business, energy, technology, markets and global industry news from Business News Today

Eylea

PharmaDeviceNews Eylea
Biocon’s Yesafili aflibercept biosimilar is gaining new clinical support for retinal treatment and diabetic macular edema ahead of its planned U.S. launch. Representative image.
Pharma & Biotech

Biocon’s Yesafili has FDA approval, but these new switching results may decide whether eye specialists embrace it

Biocon’s new Yesafili studies add switching and subgroup evidence ahead of a planned U.S. launch in the competitive aflibercept market.

Read More
Representative image showing retinal eye care and injectable ophthalmology treatment as Samsung Bioepis expands Europe’s aflibercept biosimilar market with the launch of OPUVIZ for major retinal diseases.
Pharma & Biotech

Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?

Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.

Read More
Representative image: Bayer’s planned Perfuse Therapeutics acquisition highlights the intensifying race to develop next-generation ophthalmology treatments beyond Eylea, with PER-001 adding a potential new pathway for glaucoma and diabetic retinopathy innovation.
Pharma & Biotech

Inside Bayer’s $2.45bn push to defend its ophthalmology franchise

Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.

Read More